24
Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival
The A-BRAVE trial, has shown that while 1 year of avelumab immunotherapy after standard treatment didn’t improve disease-free survival, it did significantly extend overall survival in high-r…
4 comments
556 views